Business
Cogent Biosciences Announces Creation of Cogent Research Team
Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"Names industry veteran John Robinson, PhD as Chief Scientific Officer\n New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases\n Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21\n\n\nBOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD.\n\n \n \n \n \n \n \n\n \n\"Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases,\" said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. \"I am thrilled to welcome John onboard as Cogent Biosciences' Chief Scientific Officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients.\" \nWith an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions. The Cogent Research Team is based in Boulder, Colorado. \n\"I am excited to join Cogent Biosciences and create a new center of excellence for small molecule discovery and development in the greater Boulder/Denver community,\" said John Robinson, PhD, Chief Scientific Officer of Cogent Biosciences. \"With strong support from Andy and the Cogent Board, I am confident we can build upon our already impressive team of scientists to create a portfolio of new medicines which can bring hope to patients in need.\"\nJohn joins the Cogent Bi...